Here is a list of the recent trial initiations that occurred within the myeloproliferative neoplasm cancer space.
As the cancer treatment landscape continues to grow, patients with myeloproliferative neoplasms (MPNs) and their caregivers should be aware of the various clinical trials currently being conducted — and ones they can possibly join. Here is a list of trial initiations that recently occurred.
Efficacy and Safety of Inrebic
A phase 3 clinical trial that’s investigating the efficacy and safety of Inrebic (fedratinib) is actively enrolling patients with intermediate or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
Patients considered for this trial must be at least 18 years old and have been previously treated with Jakafi (ruxolitinib).
The researchers plan to examine the percentage of patients with at least a 35% reduction of spleen volume.
The trial is happening at 32 locations within the United States and Canada.
KRT-232 Versus Jakafi
Patients with phlebotomy-dependent polycythemia vera can look to enter a global phase 2a/2b study that is evaluating KRT-232, an inhibitor of the MDM2 protein, versus Jakafi (ruxolitinib).
The trial has 50 location sites, including many across the United States, and is expected to be completed by October 2023.
In part A, patients must be resistant or intolerant to hydroxyurea, a type of chemotherapy, or have undergone treatment with interferon. They will be randomly assigned to three groups and will be given two different doses following different schedules. In part B, patients must be resistant or intolerant to hydroxyurea and will be randomly selected to recieve KRT-232 or Jakafi.
CPI-0610 With and Without Jakafi
A phase 2 clinical trial is investigating the small molecule CPI-0610 in patients with previously treated acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms and myelofibrosis. CPI-0610 inhibits the bromodomain and extra-terminal proteins.
Part one of the study will look at dosage to maximize its effect and part two will look at the agent given with or without Jakafi in patients with myelofibrosis.
The trial is open to people 18 years or older and is available at more than a dozen sites across the United States and Canada.
Overall Response Rate of Tipifarnib
Tipifarnib, which belongs to a family of drugs called farnesyltransferase inhibitors, is being examined in patients with myelodysplastic/myeloproliferative neoplasms, including those with chronic myelomonocytic leukemia and acute myeloid leukemia.
The phase 2 clinical trial will investigate the overall response rate, or the percentage of patients whose cancer shrinks or disappears after treatment. It’s open at eight centers across the United States, including Arizona, Florida, Maryland, Minnesota, New York, Ohio and Pennsylvania.
The estimated completion date is May 2022.